Zoladex
(goserelin acetate)Phase 3Small molecule
Goserelin acetate is used to treat advanced prostate cancer in men and breast cancer in women, and it can also be used to manage endometriosis and uterine fibroids. It works by reducing hormone levels in the body that fuel these conditions.[1] Zoladex is currently being investigated across 13 indications[3], with its most advanced program in Phase 3.[1]
Zoladex is one of 287 small molecule programs targeting Breast Cancer. It is currently in Phase 3.
13
Indications
81
Total Trials
15
Active Trials
286
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 13 indications
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Zoladex
TTerSera Therapeutics LLC
Phase 3
Blenoxane
Bristol-Myers SquibbPreclinical
Lexiscan
AstellasPreclinical
Voltaren
NovartisPreclinical
Zolymbus
AbbViePreclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Duragesic-100
CCephalon
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Spravato
WWim Janssens
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Prostate Cancer35 trials
Bevacizumab, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer
Unknown status·—·Phase 2·NCT00348998·18 enrolled
Show 32 more trials
Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
Recruiting·—·Phase 2·NCT04734730·70 enrolled
Management of Castration-Resistant Prostate Cancer with Oligometastases
Active, not recruiting·SSir Mortimer B. Davis - Jewish General Hospital·Phase 2/3·NCT02685397·102 enrolled
Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00021450·819 enrolled
Breast Cancer21 trials
Show 18 more trials
Metastatic Prostate Cancer7 trials
Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
Active, not recruiting·—·Phase 2·NCT00544830·29 enrolled
Show 4 more trials
Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
Active, not recruiting·—·Phase 2·NCT03361735·25 enrolled
Prostate Adenocarcinoma3 trials
14 more indications
Biochemical Recurrence1 trial
Metabolic Syndrome1 trial
Insulin Sensitivity in Men With the Metabolic Syndrome
Suspended·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·N/A·NCT00433173·72 enrolled
Radiotherapy1 trial
Bone1 trial
BMD Alterations and Bone and Muscle Parameters During Menstrual Cessation With GnRH
Completed·—··NCT04203212·41 enrolled
ESS1 trial
Androgen Deprivation Therapy1 trial
Advanced Breast Cancer1 trial
Anatomic Stage III Breast Cancer AJCC v81 trial
Prostate Carcinoma1 trial
Regulatory
FDA Approval Timeline[4]
Dec 29, 1989
ZOLADEX
NDA NDA019726
Jan 11, 1996
ZOLADEX
NDA NDA020578
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for goserelin acetate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Gonadotropin-Releasing Hormone Receptor Agonist[2]
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- TTerSera Therapeutics LLC